Speaker illustration

Professor Andrew Coats

University of Warwick, Coventry (United Kingdom of Great Britain & Northern Ireland)

Member of:

European Society of Cardiology
Heart Failure Association

Andrew J. Stewart Coats' main interest is Heart Failure. From Feb 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as CEO of the Norwich Research and Innovation Park, Deputy Vice-Chancellor and Dean of Medicine of the University of Sydney, Head of Cardiology of Imperial College, London and Associate Medical Director and Director of Cardiology of the Royal Brompton and Harefield Hospitals, London. Andrew studied Medicine at Oxford and Cambridge. He has published over 20 patents and more than 650 full research papers and more than 100,000 career citations, with a personal H-index of 135. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve at its president 2020-2022.

Unlocking the potential of baroreflex activation therapy (BAT) for HFrEF patients

Event: ESC Congress 2022

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session type: Satellite Symposium

Thumbnail

Personalized approach in real-world heart failure management: are we ready for the revolution?

Event: ESC Congress 2022

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Heart Failure 2022 highlights

Event: Heart Failure 2022

Topic: Heart Failure Association (HFA)

Session type: Special Session

Thumbnail

Lifetime Achievement Award 2022

Event: Heart Failure 2022

Topic: Heart Failure Association (HFA)

Session type: Special Session

Thumbnail

The year's best papers on heart failure

Event: Heart Failure 2022

Topic: Heart Failure Association (HFA)

Session type: Special Session

Thumbnail

Optimizing foundational therapies in patients with heart failure: from evidence to real-world clinical practice

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

A new era for HFpEF – Exploring the role of empagliflozin in practice

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session type: Satellite Symposium

Thumbnail

Late-Breaking Trials - Pharmacological treatment I

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session type: Late-Breaking Science

Thumbnail

SGLT2 inhibitors across the spectrum of heart failure

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session type: Symposium

Thumbnail

The fantastic four of heart failure treatment: do we know how to use them?

Event: Heart Failure 2022

Topic: Treatment

Session type: Debate Session

Thumbnail

This platform is supported by

logo Novo Nordisk